EXPRESSION OF NEUTROPHIL GELATINASEASSOCIATED LIPOCALIN (NGAL) ON BENIGN AND MALIGNANT EPITHELIAL OVARIAN TUMOR TISSUE

Paul Alwin Khoman, Riza Rivany, Yostoto B Kaban

Abstract


Ovarian tumors are neoplasms derived from ovarian tissue To date, malignant ovarian tumors are treated with adjuvant
chemotherapy. Several studies have reported glicoprotein such as Neutrophil gelatinase-associated lipocalin (NGAL)
have important roles as a marker for clinical response to chemotherapy and disease prognosis.
This is a comparative analytic study using samples from ovarian tissue obtained from April 2018 to September 2018. Data
were analyzed by calculating kappa values and relationships between variables using the Chi-square statistical test. P
values less than 0.05 were considered significant with 95% CIs.
NGAL expression increased significantly in grade I epithelial ovarian tumors (15 patients ;78,9%). The majority of
patients with ALLRED score (+) were found in malignant epithelial ovarian tumors (19 patients; 73,1%) and ALLRED
score (-) were most common in benign epithelial ovarian tumors.


Keywords


Ovarian Tumor, Malignant Ovarian Cancer, NGAL Expression, ALLRED.

Full Text:

PDF

References


Berek JS, ed. Berek and Novak’s Gynecology. 14th ed. Lippincott Williams and Wilkins. California. 2007.

Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, McCubrey JA, Libra M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014 Mar; 5(6): 1576-94. doi: 10.18632/oncotarget.1738

Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Estrogen-regulated Gene Expression Predicts Response to Endocrine Therapy in Patients with Ovarian Cancer. Gynecol Oncol 2007 Sep; 106(3): 461-8. Epub 2007 Jul 10.

Lim R, Ahmed N, Borregaard N, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 2007(120) : 2426–2434

Vergara D, Merlot B, Lucot JP, et al. Epithelial-Mesenchymal Transition in Ovarian Cancer. Cancer Lett 2010 May 1; 291(1): 59-66.

The American Cancer Society medical and editorial content team. What Are the Key Statistics About Ovarian Cancer? Available at: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html. Accessed: 10 April 2016

Oemiati R. Rahajeng E. Kristanto AY. Prevalensi Tumor dan Beberapa Faktor yang Mempengaruhinya di Indonesia. Bul. Penelit. Kesehat, Vol. 39, No.4, 2011: 190 – 204

Sahil MF. Penatalaksanaan kanker ovarium pada wanita usia muda dengan mempertahankan fungsi reproduksi. 2007. USU e-repository. 2008

Johari, Afiq dan Siregar F. Insidensi Kanker Ovarium berdasarkan Faktor Risiko di RSUP Haji Adam Malik Medan Tahun 2008-2011 E-Jurnal FK USU Volume 1 No.1, 2013 : 1-6

Andrea Tinelli1, et al. Ovarian Cancer Biomarkers: A Focus on Genomic and Proteomic Findings. Current Genomics, 2007, 8, 335-342

Hussain F, Hussain AN. In: Huh WK (Ed) Gynecologic Tumor Marker. January 2015. Available at: Http://emedicine.medscape.com/article/269839-overview. Accessed: 14 April 2016

Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. Journal of clinical pathology. 2013;66(4):273-81.

Pepin K, Carmen MD, Brown A, Dizon DS. CA-125 and Epithelial Ovarian Cancer: Role in Screening, Diagnosis, and Surveillance. The American Journal of Hematology/Oncology. Vol 10, No 6. December 2014. p22-29

Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994;83:799–807.

Flower DR. The lipocalin protein family: structure and function. Biochem J 1996:318 (Part 1):1–14.

Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425–32.

Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J 2005;391:441–8.

Chakraborty S, Kaur S, Tong Z, Batra SK, Guha S. Neutrophil gelatinase-associated lipocalin: structure, function, and role in human pathogenesis. In: Veas F (ed). Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins. Rijeka, Croatia: In Tech; 2011. doi: 10.5772/18755

Cho HB, Kim JH. Lipocalin2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer. Journal of Histochemistry & Cytochemistry Volume 57(5): 513–521, 2009

Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17–23.

Yang J, Goetz D, Li JY, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell. 2002 Nov; 10(5): 1045-56. doi: 10.1016/S1097-2765(02)00710-4

Pan X, Tamilselvam B, Hansen EJ, Daefler S. Modulation of iron homeostasis in macrophages by bacterial intracellular pathogens. BMC Microbiol. 2010; 10: 64. doi: 10.1186/1471-2180-10-64

Devarajan P. The promise of biomarkers for personalized renal cancer care. Kidney Int. 2010 May; 77(9): 755–7. doi: 10.1038/ki.2010.26

L.R. Devireddy, C. Gazin, X. Zhu, M.R. Green, A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell (2005) Dec 2009; 123(7): 1293–1305.

S. Candido, Maestro R, Polesel J, et al. Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochimica et Biophysica Acta 1863 (2016) 438–448.

Tong Z, Chakraborty S, Sung B, et al. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. Cancer. 2011 Jun 1;117(11):2408-18. doi: 10.1002/cncr.25803. Epub 2010 Dec 29.

Wu J, Shang AQ, Lu WY. Clinical significance of NGAL and MMP-9 protein expression in epithelial ovarian cancers. Int J Clin Exp Med. 2016; 9(2): 3069–75. Available at: Http://www.ijcem.com/files/ijcem0015882.pdf Accessed: 27 Juni 2017

Gafur A, Edianto D, Simajuntak RY, Pasaribu HP Ardiansyah E, Siregar HS. Serum Neutrophil gelatinase-associated lipocalin (NGAL) level differences in benign and malignant epithelial ovarian tumo. Bali Med .2018;7(1): 132-136

Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20:11–23.

Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol. 2003;202:97–99.

Baressi V, Bonetti LR, Gregorio C, Vitarelli E, Leon M, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathology – Research and Practice 207 (2011): 479-486.

Rusda M, Lutan D, Gafur A, Sahil MF, Ichsan TM, Haryono HL, Tala ZZ. Human Epididymis Protein 4 Immunohistochemistry Expression in Benign Ovarian Cysts. Stem Cell Oncology, 283-287.

Rusda M, Nurvita D, Yaznil MR, Aldiansyah D, Ardiansyah E, Rivany R. The Correlation of Matrix Metalloproteinase-9 Serum levels with Clinicopathological Factor in Epithelial Type Ovarian Cancer Patients. Giorn. It. Ost. Gin., 108-112.

Kumalasari C, Rusda M, Sidabutar ER, Ardiansyah E, Simanjuntak RY. The Difference Between HE4 Expression in Urine of Women with Ovarian Cysts and Women with Normal Ovary. Giorn. It. Gin., 151-157.


Refbacks

  • There are currently no refbacks.